SCHEMBL10182153

SCHEMBL10182153

CS(=O)(=O)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.59
HTT P42858 4/20 0.59
PTGS2 P35354 7/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
MAPT P10636 2/20 0.55
ALDH1A1 P00352 2/20 0.55
APOBEC3A P31941 1/20 0.55
APOBEC3G Q9HC16 1/20 0.55
TP53 P04637 1/20 0.55
ATM Q13315 1/20 0.55
KMT2A Q03164 2/20 0.50
XBP1 P17861 1/20 0.50
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PTGS1 P23219 1/20 0.47
PTGES2 Q9H7Z7 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26354332 1.00 LMNA (0.59) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL469038 0.98 LMNA (0.56) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL12473626 0.94 LMNA (0.51) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL13176976 0.90 PTGS2 (0.51) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL26154097 0.84 ALOX5AP (0.45) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL10182181 0.83 LMNA (0.68) LMNAHTTSMN1; SMN2MAPTALDH1A1
SCHEMBL10180298 0.81 LMNA (0.65) LMNAHTTSMN1; SMN2MAPTALDH1A1
SCHEMBL6788472 0.81 ESR2 (0.56) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL22817130 0.81 ESR2 (0.55) LMNAHTTPTGS2SMN1; SMN2MAPT
SCHEMBL22816222 0.81 ESR2 (0.55) LMNAHTTPTGS2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170184973-A1 ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, METHOD OF PRODUCING ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, STORAGE CONTAINER OF ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, PATTERN FORMING METHOD USING THE SAME, AND METHOD OF PRODUCING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2017-06-29 US disclosed
US-20140086936-A1 MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS SOCPRA Sciences Sante et Humaines S.E.C. (CA) 2014-03-27 US disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170184973-A1 ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, METHOD OF PRODUCING ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, STORAGE CONTAINER OF ORGANIC TREATMENT LIQUID FOR PATTERNING RESIST FILM, PATTERN FORMING METHOD USING THE SAME, AND METHOD OF PRODUCING ELECTRONIC DEVICE MYB, NCL, SMYD2 LMNA 2142/4885HTT 2213/4885PTGS2 3559/4885
US-20140086936-A1 MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS MMP7, MATR3, ADAMTS1 LMNA 3507/4885HTT 3714/4885PTGS2 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.